Movement Alert｜Pharmaron Rises 5.69% in Regular Trading, H1 Earnings Forecast Beats Expectations Amid CRO Industry Order Recovery

Market Focus07-20

On July 20, Pharmaron rose 5.69% in regular trading, trading at 24.48 HKD/share, with turnover of approximately 73.97 million HKD.

The rally was driven by the company's recently disclosed H1 earnings forecast exceeding market expectations, combined with a broad recovery in CRO industry orders. Pharmaron guided H1 revenue of 7.47-7.67 billion yuan, up 16%-19% YoY, and attributable net profit of 729-772 million yuan, up 4%-10% YoY. Notably, newly signed orders surged over 30% YoY, with small-molecule CDMO new orders jumping over 50%, while Q2 performance showed clear acceleration versus Q1.

At the industry level, CRO sector orders have broadly recovered, with leading companies reporting backlog growth exceeding 40% YoY. Analysts believe the CXO rebound is backed by solid earnings fundamentals. Additionally, JP Morgan recently increased its stake by approximately 1.29 million shares at around 22.11 HKD per share, while Daiwa initiated coverage with a Buy rating and a target price of 25.5 HKD.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1172340208?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-20 10:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1172340208","market":"us","top_or_hot":-1,"title":"Movement Alert｜Pharmaron Rises 5.69% in Regular Trading, H1 Earnings Forecast Beats Expectations Amid CRO Industry Order Recovery","media":"Market Focus","content":"<p><p>On July 20, Pharmaron rose 5.69% in regular trading, trading at 24.48 HKD/share, with turnover of approximately 73.97 million HKD.</p><p>The rally was driven by the company's recently disclosed H1 earnings forecast exceeding market expectations, combined with a broad recovery in CRO industry orders. Pharmaron guided H1 revenue of 7.47-7.67 billion yuan, up 16%-19% YoY, and attributable net profit of 729-772 million yuan, up 4%-10% YoY. Notably, newly signed orders surged over 30% YoY, with small-molecule CDMO new orders jumping over 50%, while Q2 performance showed clear acceleration versus Q1.</p><p>At the industry level, CRO sector orders have broadly recovered, with leading companies reporting backlog growth exceeding 40% YoY. Analysts believe the CXO rebound is backed by solid earnings fundamentals. Additionally, JP Morgan recently increased its stake by approximately 1.29 million shares at around 22.11 HKD per share, while Daiwa initiated coverage with a Buy rating and a target price of 25.5 HKD.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Pharmaron Rises 5.69% in Regular Trading, H1 Earnings Forecast Beats Expectations Amid CRO Industry Order Recovery</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Pharmaron Rises 5.69% in Regular Trading, H1 Earnings Forecast Beats Expectations Amid CRO Industry Order Recovery\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-20 10:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 20, Pharmaron rose 5.69% in regular trading, trading at 24.48 HKD/share, with turnover of approximately 73.97 million HKD.</p><p>The rally was driven by the company's recently disclosed H1 earnings forecast exceeding market expectations, combined with a broad recovery in CRO industry orders. Pharmaron guided H1 revenue of 7.47-7.67 billion yuan, up 16%-19% YoY, and attributable net profit of 729-772 million yuan, up 4%-10% YoY. Notably, newly signed orders surged over 30% YoY, with small-molecule CDMO new orders jumping over 50%, while Q2 performance showed clear acceleration versus Q1.</p><p>At the industry level, CRO sector orders have broadly recovered, with leading companies reporting backlog growth exceeding 40% YoY. Analysts believe the CXO rebound is backed by solid earnings fundamentals. Additionally, JP Morgan recently increased its stake by approximately 1.29 million shares at around 22.11 HKD per share, while Daiwa initiated coverage with a Buy rating and a target price of 25.5 HKD.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03759","symbol_name":"康龙化成","start_time":0,"source_url":"","article_id":"1172340208","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1172340208","pubTimestamp":1784512974,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 20, Pharmaron rose 5.69% in regular trading, trading at 24.48 HKD/share, with turnover of approximately 73.97 million HKD.The rally was driven by the company's recently disclosed H1 earnings...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03759":"康龙化成"},"translate_title":"走势提醒|康龙化成常规交易上涨5.69%，CRO行业订单复苏，上半年盈利预测超预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03759":1},"content_text":"On July 20, Pharmaron rose 5.69% in regular trading, trading at 24.48 HKD/share, with turnover of approximately 73.97 million HKD.The rally was driven by the company's recently disclosed H1 earnings forecast exceeding market expectations, combined with a broad recovery in CRO industry orders. Pharmaron guided H1 revenue of 7.47-7.67 billion yuan, up 16%-19% YoY, and attributable net profit of 729-772 million yuan, up 4%-10% YoY. Notably, newly signed orders surged over 30% YoY, with small-molecule CDMO new orders jumping over 50%, while Q2 performance showed clear acceleration versus Q1.At the industry level, CRO sector orders have broadly recovered, with leading companies reporting backlog growth exceeding 40% YoY. Analysts believe the CXO rebound is backed by solid earnings fundamentals. Additionally, JP Morgan recently increased its stake by approximately 1.29 million shares at around 22.11 HKD per share, while Daiwa initiated coverage with a Buy rating and a target price of 25.5 HKD.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1172340208","isCrawlerRequest":true}